Focus on Cancer

Host: Shira Johnson, MD

Guest: Edmond Bendaly, MD, FACP

From VEGF and EGFR-targeted therapies to emerging immunotherapies, there are several treatment options available to mCRC patients…but that also means that there’s several factors you need to think about before deciding which option is best for each individual patient. Here to break everything down with Dr. Shira Johnson is Dr. Edmond Bendaly, chairman and liaison of the Cancer Committee at Marion General Hospital in Marion, Indiana.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Richard Kim, MD

Join Dr. Richard Kim of Moffitt Cancer Center as he reveals how the sidedness of a mCRC tumor affects not only the prognosis, but also the biologic you use for each individual patient.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Richard Kim, MD

Performing KRAS testing is an essential step clinicians need to take to determine which therapeutic option is best. In fact, skipping this step can actually be detrimental to patients. Here to talk about the important role of KRAS testing in metastatic colorectal cancer is Dr. Richard Kim, Medical Oncologist at Moffitt Cancer Center.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Richard Kim, MD

There’s much to consider when it comes to determining which therapeutic option is best for your metastatic colorectal cancer patients, which is why Dr. Richard Kim is here to walk us through his thought process using this patient case review.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Guest: Edmond Bendaly, MD, FACP

Dr. Edmond Bendaly from the Cancer Committee at Marion General Hospital in Indiana shares a patient case that stands out from the rest—and proves the importance of consistently monitoring for side effects.

Conversations on Colorectal Cancer is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Host: John J. Russell, MD

Guest: Richard Wender, MD

From oncologists to primary care, physicians are witnessing an alarming trend in younger patients: the rising risk of colorectal cancer. To investigate this growing threat, Dr. John Russell speaks with Dr. Rich Wender, Chief Cancer Control Officer at the American Cancer Society. Dr. Wender discusses the new colorectal cancer screening guidelines set forth and the methods behind the conclusion. While comparing past guidelines, Dr. Wender considers changes in our society and environment that may be contributing to increased cancer risks in younger generations.

For more information and to review the new guidelines, go to cancer.org

Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.

Released on December 21, 2017

Host: Amy Mackey, MD

Guest: Mark Spitzer, MD

Prior to 2012 there were competing cervical cancer screening guidelines from the American Cancer Society and the United States Preventive Services Task Force (the USPSTF), leading providers to follow their own dictates when screening patients. In this edition of Advances in Women’s Health, host Dr. Amy Mackey is joined by Dr. Mark Spitzer with the Center for Colposcopy in New Hyde Park, Long Island, New York to discuss cervical cancer screening updates, including the current consensus guidelines, the interim guidance on HPV primary screening, and the latest data on cytology and co-testing. Click here to learn more about other women's health programs in this special series.

What is hereditary cancer and why is genetic testing important to understand a patient's risk? Cancer is complex and has many causes. Most cancers are sporadic, but about 10 to 15 percent of certain cancers are due to harmful genetic changes called mutations that are passed down through families. Learning whether your patient is at risk for hereditary cancer can help you as a healthcare provider to develop a screening and prevention plan that may help identify cancer at an earlier stage. Because men and women with mutations have a 50% chance of passing their mutation to each of their children, learning about hereditary cancer risk is not only important for your patient, but also their family members. Learn more about Color’s Hereditary Cancer Test and the unique program it offers, including complimentary access to genetic counselors. Learn more about how Color is working with healthcare providers to bring affordable, accessible, and actionable genetic testing to patients at color.com/providers/contact.

Host: Shira Johnson, MD

Guest: Robert Vonderheide, MD

For years, the foundations of cancer treatment, surgery, chemotherapy, and radiation therapy were utilized with the objective of weakening cancer.

But over the past several years, immunotherapy – therapies that enlist and strengthen the power of a patient’s immune system to attack tumors - has emerged as a new tool for fighting cancer. In August 2017, one such treatment approach, called Chimeric Antigen Receptor or CAR T-cell Therapy, received FDA approval for the treatment of children and young adults with acute lymphoblastic leukemia (ALL). Additionally, research is continuing to look at CAR-T therapy’s effectiveness for treating solid tumors as well.

Host Dr. Shira Johnson sits down with Dr. Robert Vonderheide, Director of the Abramson Cancer Center of the University of Pennsylvania and the John H. Glick, MD, Abramson Cancer Center Director’s Professor, to talk about the potential of CAR-T therapy alongside other emerging immunotherapies in fighting cancer.